Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a report published on Saturday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

NASDAQ ORMP opened at $2.45 on Friday. The company has a market cap of $98.76 million, a P/E ratio of 22.27 and a beta of 1.67. Oramed Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.67. The company has a 50-day moving average of $2.38 and a 200-day moving average of $2.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd raised its holdings in shares of Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares during the period. Murchinson Ltd. increased its position in Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after purchasing an additional 8,889 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Oramed Pharmaceuticals in the third quarter valued at approximately $272,000. BML Capital Management LLC lifted its position in Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after buying an additional 837,153 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares in the last quarter. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.